|
|
A Longitudinal Investigation of Psychotropic and N...[J
Autism Dev Disord. 2009] - PubMed Result
PubMed
Investigation, May 2009
|
|
|
Approval process lowers the number
of kids on atypical prescriptions (USA)
By Kris Hundley, Times Staff Writer,
St. Petersburg Times
Sunday, March 29, 2009
Nudged by public pressure, Florida health
officials took a baby step last year toward reining in the use of powerful
antipsychotic drugs among children: They began requiring that doctors
get approval before giving these drugs to kids under 6 on the Medicaid
program.
That simple step prompted a seismic
change in doctors' prescribing habits. The
number of prescriptions of these potent drugs to kids in this age group
plummeted nearly 75 percent.
Full
story and space to comment
|
|
|
APANA news
headlines 2008 | APANA news
headlines 2007
|
|
Sandrine Bonnaire's film about her sister, available
on DVD.
"a brilliant documentary feature film about an
autistic woman whose spark and vitality and intelligence and will to
participate were all demolished by treatment with neuroleptics"
"See this film, you will not regret it!"
|
|
|
Autism Information Library
Autobiography
of Anonymous
|
|
Crazy adverts for crazy products
Feb 20, A look at some major medication, the ads they use, and the side-effects they have.
(link to Bonkers
Institute)
|
|
APANA: America Approves Antipsychotic Drug for Teens
23 AUG 07: In case you missed this. WSJ
report.
Yes, those are Lego blocks (actual Lego blogs, a kid
can build w/them), a cookie or candy dispenser (literally, it's a
cookie/candy dispenser, according to J&J), and microwave popcorn,
all of which advertise Risperdal.
|
| |
|
According
to Bazire's professionals' pocket handbook 'Psychotropic
Drug Directory' 2003-2004 p25:
"...autistic
individuals seem very sensitive [to antipsychotics] and
so lower doses may be needed. A therapeutic window may
exist with higher doses counter-productive." |
|
| The
Pills in Question:
Neuroleptic/antipsychotic medications |
| Generic
name 1st then UK brand name
Benperidol=Anquil: Chlorpromazine=Largactil:*Clozapine=Clozaril:
Droperidol=Droleptan: Flupenthixol=Depixol;Fluanxol:Flupenthixol
decanoate=Depixol:*Fluspiriline=Redemptin depot: Haloperidol=Serenace,
Haldol, Dozic:Haloperidol decanoate=Haldol Decanoate:
Loxapine=Loxapac:Methotrimeprazine/Levomepromazine=Nozinan:
*Olanzapine=Zyprexa:*Oxypertine=Oxypertine:Pericyazine=Neulactil:Perphenazine=Fentazin:Pimozide=Orap:
Pipothiazine decanoate=Piportil depot: Prochlorperazine=Stemetil:
Promazine=Sparine: *Quetiapine=Seroquel: *Remoxipride=Roxiam:*Risperidone=Risperdal:
*Sertindole= Serdolect :Sulpiride=Dolmatil, Sulparex,
Sulpitil:Thioridazine=Melleril: Trifluoperazine =Stelazine
:Zucopenthixol decanoate=Clopixol depot: Zuclopenthixol=Clopixol
*"atypical", more recent, antipsychotics
which may not have such severe immediate side effects
but many are implicated in heart problems and extreme
weight gain.
|
| |
|
|
|
| Some useful references which
add up to the conclusion that people on the
autistic spectrum are uniquely likely to be
inappropriately prescribed harmful antipsychotics
(see list of effects below): Autisme- Europe:
1999: European code of good practice for the
prevention of Violence and Abuse against People
with Autism: Brussels: DAPHNE/Autisme-Europe;
Bhaumik S, Branford D, McGrother C, Thorp
C: 1997: Autistic traits in adults with learning
disabilities: British Journal of Psychiatry:170:
502-506; Branford, D: 1996: A review of antipsychotic
drugs prescribed for people with learning
disabilities who live in Leicestershire: Journal
of Intellectual Disability Research: 40: 4:
358-368). Manchester, D: 1993: Neuroleptics,
learning disability, and the community: some
history and mystery: British Medical Journal:
307: 17 July: 184-187, Murray,D (1999) Potions
Pills and Human Rights, Good Autism Practice
vol 1,no1,pp71-84 or go to http://www.autismandcomputing.org.uk/potions.htm
for a longer version; Robertson, Emerson et
al (in press) Receipt of Psychotropic Medication
for People with Intellectual Disabilities
in Residential Settings. |
|
|
| |
|
|
Side
effects of neuroleptic medications
(compiled from manufacturers' datasheets and
elsewhere )
* signifies an effect which may be easily
missed in those who do not self-report
|
| Frequent
onset effects, sometimes fade
with time
Blurred vision*
Breast enlargement, milk flow
Constipation*
Decreased sweating*
Dizziness, low blood pressure*,
falls
Drowsiness* Dry mouth*
Headache*
Increased skin-sensitivity to
sunlight*
Lightheadedness*
Menstrual irregularity or absence
Sexual difficulty*, decline
in libido*, genital pain* |
|
|
| Other
Catatonic
decline
NMS neuroleptic malignant syndrome:
a condition marked by muscle
stiffness or rigidity, dark
urine, fast heartbeat or irregular
pulse, increased sweating, high
fever, and high or low blood
pressure.
Unchecked this condition can
prove fatal. Call the doctor
immediately if you notice any
of these symptoms. NB newer
neuroleptics appear just as
likely to provoke this syndrome.Torsades
de Pointes: a condition which
affects the heart rhythm and
can lead to sudden cardiac arrest,
when it is usually fatal.
|
|
Effects
which typically remain, worsen or appear
with prolonged use
Cataracts*
Difficulty urinating*
Difficulty talking*
Difficulty swallowing*
Eyes turning upwards
Fatigue*
Lassitude/torpor
Tardive dyskinesia (movement disorder)
Tongue edge "snaking"*(early sign of
movement disorder)
Jerky movements of head, face, mouth
or neck
Muscle spasms of face, neck or back,
twisting the neck muscles
Restlessness, physical and mental* resulting
in sleep difficulty
Restless legs resulting in inability
to sit down
Saliva drooling
Seizure threshold lowered
Skin rashes, itches, discolouration
Sore throat*
Staring looks
Stiffness of arms or legs*
Swelling of feet
Trembling of hands
Uncontrollable chewing movements
Uncontrollable lip movements, puckering
of the mouth
Uncontrollable movements of arms and
legs
Unusual twisting movements of body
Weight gain
Yellow eyes, skin (indicate liver problem
|
|
| Frequently
found symptoms of abrupt withdrawal from
neuroleptics |
| nausea*
emesis weight loss
diarrhoea rhinorrhoea (runny nose)
diaphoresis (heavy sweating)
myalgias (stabbing pains)* paresthesias
(odd sensations, eg burning feelings,etc)*
anxiety* agitation
restlessness insomnia increased
tremor (unmasked by withdrawal)
|
|
HAVE
YOU GOT A STORY TO TELL?
APPEAL FOR INFORMATION - OPPORTUNITY TO TALK TO
A LAWYER
|
| The use of prescribed drugs - especially
antipsychotics - drugs to control the "challenging
behaviour" of people with learning difficulties
or autistic disorders has been of concern for many
years. The Government has now officially recognised
the problem in its recent White Paper, Valuing People:
A New Strategy for Learning Disability for the 21st
Century: Studies of the management of people
with challenging behaviour have shown an over-dependence
on the use of psychotropic drugs with poor outcomes
as a result. (p60)
There are concerns that alternatives are not
properly considered before the use of drugs, many
of which carry risks of side effects which can
cause social exclusion as well as physical harm.
Where the individual mentally incapable of making
the decision him/herself, treatment can only be
given if it is in his/her best interests*. The
"best interests" test is not just a
question of whether the treatment is acceptable
medical practice. Ethical, moral, social and welfare
considerations are also relevant. The availability
of a less restrictive or invasive approach - such
as addressing communication difficulties which
may generate "challenging behaviour"
- is of particular importance.
APANA (Autistic People Against Neuroleptic Abuse)
is concerned that the rights of people with learning
difficulties and autistic disorders should be
properly and fully respected in treatment decisions.
The group, with the help of their legal advisers,
is hoping to take up these issues with the Department
of Health. If you or a member of your family has
been prescribed psychotropic drugs to control
behaviour, or this is currently being proposed,
and you are unhappy with the treatment decision
or have noticed unwanted side effects, APANA would
like to hear from you. All information given would
be treated in confidence unless you give your
permission for it to be used.
Please contact Karen Ashton through Tyndallwoods
Solicitors on [UK] 0121 243 3139.
* If the person is detained under the Mental
Health Act 1983, the Act itself permits treatment
in the absence of the patient's consent, whether
they are incapacitated or not, but only in certain
circumstances.
|
|
|
| March 2001
Some quotes from UK Government
White Paper Valuing People: A New Strategy
for Learning Disability for the 21st Century
"Studies of the management
of people with challenging behaviour has shown
an over-dependence on the use of psychotropic
drugs with poor outcomes as a consequence." p67
"Challenging behaviours
are best thought of as being a way in which people
respond and try to gain control over difficult
situations. Psychotropic medication may be very
effective when there is an underlying psychiatric
disorder but there is concern that too often this
medication is used as an alternative to adequate
staffing." p110 |
|
|
|
